In medical technology development, there are perennially long-shot technologies being pursued for their ability to make an order of magnitude shift in treatment. This, of course, seems to be the thrust of a majority of biotechnology development, which seeks to provide cures where only palliative treatments (drug or device) currently exist, such as in gene [...]
Stenting is not ideal for all patients with coronary heart disease, such as those with left main or three (or more) vessel disease. However, the vast majority of cardiovascular disease patients can benefit from the benefits of PCI, not the least of which include a shorter recovery period and less trauma to the patient.
The global [...]
(The global market for coronary stents worldwide is assessed in the MedMarket Diligence report #C245, "Worldwide Market for Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017.")
The market for coronary stents in Asia and the Pacific region contains both China (early technology adopters) and Japan (with a longer regulatory approval cycle), which generated a combined majority [...]
Market drivers that vary geographically account for some big differences in the distribution of the coronary stent market across the currently available stent types, and these differences will continue when bioabsorbable stents (and others) are introduced to the market over the next few years.
The local market forces dictating these differences include:
Regulatory timelines in one market [...]
My posts on advanced medical technology, drawing frequently from our market reports, are worth emphasizing for their global perspective. Some two decades ago, it became apparent to me that that the global market perspective is not reserved for big, multi-national companies and their global presence. My understanding of this came about from the experience of [...]
The coronary stent market has represented a marvelous opportunity for many medical technology companies, but even though it is a huge market now, and has generated enormous cash flow for early entrants, it runs significant risk for current manufacturers as well as those seeking to gain share of this multi-billion dollar global market. The reason [...]
In the $7 billion+ worldwide market for drug-eluting coronary stents, a consistent theme is now the myriad challenge to existing players from the host of emerging competitors, particularly since the advent of drug-eluting stents (DES). Although not so long ago the DES market was monopolized by J&J/Cordis, then split and controlled by J&J and Boston [...]
The evolution of the coronary stent market, like most medical device markets, has been driven by manufacturers focused on expanding the use of coronary stents into new caseload as well as penetrating the market shares of competitors.
Clinicians, for their turn as gatekeepers in this effort, are guided in the adoption of stent technologies by [...]
Perhaps in no other market is it more imperative for current competitors to keep their eyes on the horizon than in the market for treatments of coronary artery disease. As I have ranted previously (search "coronary artery disease" on this blog), alternative treatments stretch from device to surgery to biotech and options too difficult to [...]
Below is an excerpt from "Worldwide Wound Management Market, 2008-2017," published by MedMarket Diligence.
A wide range of regulatory approval conditions are applied to wound management products. The decision about regulatory classification for a given wound management product lies with the regulatory authority of the country in which the product is to be marketed and the [...]
Contact:
